New Science Ventures, LLC (NSV) is a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value. NSV invests in companies using science-based innovations to address market needs in Life Sciences (pharmaceuticals, biologics, medical devices, and diagnostics) and Information Technology (e.g., high-performance semiconductors, cellular infrastructure, sensor networks, enterprise software, and storage) sectors.
NSV was founded in 2004 by Somu Subramaniam, Managing Partner, and Tom Lavin, Partner, and has invested approximately $500 million in early, mid- and late stage companies located in the U.S., Europe, India and China.
NSV targets investments in companies that are based on fundamental, science-based innovation, satisfy an unmet need and/or have a substantially better value proposition than current solutions, and address large markets, often with more than $1 billion in potential revenue. We invest in companies that have strong management, have defensible intellectual property, and are attractively valued so that large gains are possible.
NSV has a comprehensive strategy to maximize value for our portfolio companies and for our investors. We are actively engaged in portfolio company activities, almost always serve on Boards of Directors, and frequently lead investments. Our team has substantial expertise in areas that are most relevant to helping our companies succeed: strategy and corporate planning, operations and cost management, and leadership development. A unique feature of NSV’s investment strategy is that we often invest in our companies across funds and timeframes. This enables us to provide capital efficiently and in a manner that corresponds to the typical development of portfolio companies over time.
The NSV Team
Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Ralexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Oxyrane UK, Resolve Therapeutics, Svelte Medical Systems, Vascular Therapies, Vaultive, and iCAD. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco) and K2M (acquired by Welsh Carson). Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
Partner & Chief Financial Officer
Tom Lavin is a co-founder of New Science Ventures and its Chief Financial Officer, responsible for financial, legal and administrative matters. He serves on the Board of Directors for Achronix Semiconductor Corporation, Light Sciences Oncology, and RF Arrays, Inc. and is an observer on the boards of Vorago, Juventas Therapeutics, Therox and Directed Sensing. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was a senior professional in finance and investment banking for over 30 years. Tom has extensive experience in private and public equity and debt transactions, mergers and acquisitions and financial restructurings in the U.S. and abroad. He was head of real estate investment banking at First Boston and Smith Barney and head of commercial mortgage lending at MetLife. Tom holds an A.B. degree in Government from Wesleyan University and an M.B.A. from Harvard Business School.
Vivek Mohindra joined New Science Ventures as a Partner in April, 2013. He serves on the Board of Directors of Caringo, Directed Sensing, Ferric Semiconductor, Mangstor, Vorago, BrightVolt, Fuzzy Logix and GlobalFoundries. He has previously served on the Board of Directors of Sensor Platforms (acquired by Audience). Vivek joined NSV from TPG Capital where he was an Operating Group Partner working with portfolio companies on strategy, growth and operational issues, and with deal teams on due diligence. Prior to TPG, Vivek served as Senior Vice President of Strategy and Business Transformation for Freescale Semiconductor and held several senior executive roles in Dell’s Product Group, Marketing division and as Vice President/General Manager of Dell’s North America SMB Group. Vivek joined Dell from McKinsey & Company where he was a Partner. At McKinsey, he was co–leader of McKinsey’s global Semiconductor practice, as well as its Asian High Tech & Telecoms practices based in Seoul. Vivek holds a B.E. degree in Chemical Engineering from the Indian Institute of Technology (Roorkee) in addition to an M.B.A. and a Ph.D. in Chemical Engineering in Semiconductor Processing from the Massachusetts Institute of Technology.
Grace Colón joined New Science Ventures in January 2014 and is currently a Senior Advisor to the firm. She serves on the Boards of ProterixBio (Executive Chairman; formerly CEO); Paradigm Diagnostics and PerceptiMed. She is also CEO of Incarda Therapeutics; advisor of Kiverdi and is on the Board of Cocoon Biotech. Prior to NSV, Grace was President of the Industrial Products Division and Senior Vice President at Intrexon Corporation and held several senior leadership roles at Gilead Sciences and Affymetrix. While at Affymetrix, she was also founding Chief Operating Officer of the International Genomics Consortium. Earlier in her career Grace worked at McKinsey & Company, where she served clients in Healthcare, High Tech, Consumer Goods and Venture Capital. She was also an engineer with Merck & Co. in France. From 2014 she has served on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Grace holds a B.S. degree in Chemical Engineering from the University of Pennsylvania (where she was a Benjamin Franklin Scholar) and a Ph.D. in Chemical Engineering (with a focus on biochemical engineering) from the Massachusetts Institute of Technology.
Partner and Senior Advisor
John L. Cecil joined New Science Ventures as a Partner and Senior Advisor in April 2014. John is Chairman and CEO of Eagle Knolls Capital and a Senior Advisor to Epoch Investment Partners. Previously, he was Chairman of CP Kelco, a specialty chemicals company and a leading manufacturer of organic hydrocolloids. Until 2000, John was Chief Financial and Administrative Officer of Lehman Brothers, and was a member of the Firm’s Operating and Executive Committees. Prior to Lehman, he was a Director at McKinsey & Company, serving as a leader of both its Information Technology and Media Practice and its Strategy Practice. John holds an A.B. degree from Princeton University, an M.B.A. from Harvard Business School, and a J.D. from Harvard Law School.
Partner and Senior Advisor
Jean-Pierre Bizet joined New Science Ventures as a Partner and Senior Advisor in February 2015. Jean-Pierre is a non-executive director on several company boards, and a professor of strategy at Université Libre de Bruxelles. Previously, he was CEO of D’Ieteren, a listed diversified company in various distribution segments of the automobile sector. Until 2002, JP was CEO of GIB Group, a diversified retail group. Prior to GIB, JP was a Director at McKinsey & Company, serving European clients from the Paris Office, and serving as a co-leader of the firm’s Change Management practice. JP holds a PhD in Applied Economics from U. of Brussels, an M.B.A. from Harvard Business School, and a M.S. from Solvay Brussels School of Economics & Management.
Andrew Abrams joined New Science Ventures in September 2016. He was formerly an Associate in J.P. Morgan’s healthcare investment banking practice in London, where he focused on mergers and acquisitions and debt and equity transactions in Europe and the US. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and service sub-sectors. Andrew holds B.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge (where he was a Richard Perham Scholar), and participated in Cambridge’s year-long exchange program with the Massachusetts Institute of Technology. He also holds an M.B.A. from Harvard Business School.